Encube Ethicals has halted plans for a majority stake sale due to a valuation gap, with potential buyers offering up to $1.6 billion against the company’s $2 billion target. Instead, the pharmaceutical firm is now eyeing an Initial Public Offering by 2027. Existing investor Quadria Capital is expected to participate in the public offering for a partial exit.